This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Famitinib
DrugBank Accession Number
DB11741
Background

Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 410.493
Monoisotopic: 410.211804288
Chemical Formula
C23H27FN4O2
Synonyms
Not Available
External IDs
  • SHR1020

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as pyrrolopyridines. These are compounds containing a pyrrolopyridine moiety, which consists of a pyrrole ring fused to a pyridine. Pyrrole is 5-membered ring consisting of four carbon atoms and one nitrogen atom. Pyridine is a 6-membered ring consisting of five carbon atoms and one nitrogen center.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolopyridines
Sub Class
Not Available
Direct Parent
Pyrrolopyridines
Alternative Parents
Indolines / Aryl fluorides / Substituted pyrroles / Benzenoids / Pyridines and derivatives / Vinylogous amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives / Trialkylamines
show 7 more
Substituents
Amine / Amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
768FW21J3L
CAS number
1044040-56-3
InChI Key
GKEYKDOLBLYGRB-LGMDPLHJSA-N
InChI
InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-
IUPAC Name
(3Z)-3-({5-[2-(diethylamino)ethyl]-3-methyl-4-oxo-1H,4H,5H,6H,7H-pyrrolo[3,2-c]pyridin-2-yl}methylidene)-5-fluoro-2,3-dihydro-1H-indol-2-one
SMILES
CCN(CC)CCN1CCC2=C(C(C)=C(N2)\C=C2/C(=O)NC3=CC=C(F)C=C23)C1=O

References

General References
Not Available
PubChem Compound
16662431
PubChem Substance
347828099
ChemSpider
17595500
BindingDB
50331023
ChEMBL
CHEMBL1278146

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentMetastatic Colorectal Cancer (CRC) / Recurrent Colorectal Cancer1
3Not Yet RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
3RecruitingTreatmentGastrointestinal Stromal Tumor (GIST)1
3RecruitingTreatmentNon-squamous Non-small-cell Lung Cancer (NSQ NSCLC)1
3TerminatedTreatmentNon Squamous Non Small Cell Lung1
2Active Not RecruitingTreatmentSolid Tumors1
2Active Not RecruitingTreatmentTriple Negative Breast Cancer1
2CompletedTreatmentColorectal Cancer / Metastatic Colorectal Cancer (CRC) / Recurrent Colorectal Cancer1
2CompletedTreatmentMetastatic Nasopharyngeal Carcinoma / Recurrent Nasopharyngeal Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0708 mg/mLALOGPS
logP3.44ALOGPS
logP2.68ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)11.46ChemAxon
pKa (Strongest Basic)9.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area68.44 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity119.31 m3·mol-1ChemAxon
Polarizability46.14 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 20:43 / Updated at June 12, 2020 16:53